Cargando…
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
Natural killer (NK) cell-based treatments are promising therapies for multiple myeloma (MM). Carfilzomib (CFZ), is a second-generation proteasome inhibitor, used to treat relapsed and refractory MM. In this study, we determined that CFZ treatment enhanced the sensitivity of MM cells to NK cell-media...
Autores principales: | Yang, Guang, Gao, Minjie, Zhang, Yiwen, Kong, Yuanyuan, Gao, Lu, Tao, Yi, Han, Ying, Wu, Huiqun, Meng, Xiuqin, Xu, Hongwei, Zhan, Fenghuang, Wu, Xiaosong, Shi, Jumei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694968/ https://www.ncbi.nlm.nih.gov/pubmed/26323098 |
Ejemplares similares
-
Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
por: Gao, Lu, et al.
Publicado: (2015) -
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016) -
Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015) -
Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials
por: Gao, Minjie, et al.
Publicado: (2014) -
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
por: Wang, Houcai, et al.
Publicado: (2016)